2007
DOI: 10.1590/s0036-46652007000300007
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: SUMMARYNucleic Acid Testing (NAT) as a tool for primary screening of blood donors became a reality in the end of the 1990 decade. We report here the development of an "in-house" RT-PCR method that allows the simultaneous (multiplex) detection of HCV and HIV-RNA in addition to an artificial RNA employed as an external control. This method detects all HIV group M subtypes, plus group N and O, with a detection threshold of 500 IU/mL. After validation, the method replaced p24 Ag testing, in use for blood donation … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(6 citation statements)
references
References 13 publications
(16 reference statements)
0
6
0
Order By: Relevance
“…[27][28][29][30][31] Nucleic acid-based tests and tests focusing on the p24 antigen are particularly important for testing when antibody production is not yet detectable in patients shortly after infection and when the host's immune system is compromised. 32,33 Another focus in diagnostic testing is the discrimination of HIV-1 and HIV-2 infections 33 and the availability of tests that can be used for point of care testing and in countries under difficult conditions where laboratory facilities are lacking and costs are an important issue.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[27][28][29][30][31] Nucleic acid-based tests and tests focusing on the p24 antigen are particularly important for testing when antibody production is not yet detectable in patients shortly after infection and when the host's immune system is compromised. 32,33 Another focus in diagnostic testing is the discrimination of HIV-1 and HIV-2 infections 33 and the availability of tests that can be used for point of care testing and in countries under difficult conditions where laboratory facilities are lacking and costs are an important issue.…”
Section: Discussionmentioning
confidence: 99%
“…The HIV microarray may well be used also for serological diagnosis of HIV infections but it must be born in mind, that currently available screening procedures that combine different antigen-antibody assays and nucleic acid based assays offer extremely high sensitivity and specificity. [27][28][29][30][31] Nucleic acid-based tests and tests focusing on the p24 antigen are particularly important for testing when antibody production is not yet detectable in patients shortly after infection and when the host's immune system is compromised. 32,33 Another focus in diagnostic testing is the discrimination of HIV-1 and HIV-2 infections 33 and the availability of tests that can be used for point of care testing and in countries under difficult conditions where laboratory facilities are lacking and costs are an important issue.…”
Section: Discussionmentioning
confidence: 99%
“…Sensitivity was neither reduced nor improved, and specificity was superior to 99.9%, as before. Main modifications were: increase in the cDNA input from 5 µL to 10 µL; replacement of a conventional enzyme Taq Polymerase by an enzyme providing higher processivity and "hot-start" namely Platinum Taq (Invitrogen, São Paulo, Brazil); addition of glycerol and cresol red; adoption of an enzymatic control of contamination provided by amplification in the presence of dUTP instead of dTTP and addition of UNG 21 .…”
Section: D6) External Assessmentmentioning
confidence: 99%
“…4), replacing p24 Ag detection 21 . Until July 2005 139,678 donations were tested for HCV RNA, including 77,555 also tested for HIV RNA.…”
Section: B) Blood Donors Screeningmentioning
confidence: 99%
“…Despite this, screening techniques can produce false-negative results for acute HIV infection and false-positive results for HIV vaccine recipients who are not sick and newborns who have passive maternal antibodies produced by mothers who are HIV-positive [11,12]. To control the infection, it is crucial to apply the molecular approach in addition to the rapid HIV-1/2 antibody-based tests among potential blood donors [13,14].…”
Section: Introductionmentioning
confidence: 99%